Publications by authors named "Fenghe Lu"

Claim this Profile
B
Bioequivalence of Preservative-Free and Preserved Omidenepag Isopropyl 0.002% Ophthalmic Solutions in Patients With Primary Open Angle Glaucoma or Ocular Hypertension: Phase 3 DAISY Study.
Makoto Aihara, Fenghe Lu, Toshihiro Ikeda, Noriko Odani-Kawabata

J Glaucoma· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
Jason Bacharach, Jacob W Brubaker, David G Evans, Fenghe Lu, Noriko Odani-Kawabata

Am J Ophthalmol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial.
Tsing Hong Wang, Tin Aung, Da-Wen Lu, Ronnie George, Sirisha Senthil, Fenghe Lu

Clin Ophthalmol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Najam A Sharif, Noriko Odani-Kawabata, Fenghe Lu, Leonard Pinchuk

Exp Eye Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.
David L Wirta, Yasuaki Kuwayama, Fenghe Lu, Hui Shao, Noriko Odani-Kawabata

J Ocul Pharmacol Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata

Jpn J Ophthalmol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
Kenneth W Olander, Michelle A Sato, Marc A Abrams, Gary W Jerkins, Fenghe Lu

J Glaucoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata

Am J Ophthalmol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Makoto Aihara, Auli Ropo, Fenghe Lu, Hisashi Kawata, Akihiro Iwata

Jpn J Ophthalmol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Yuki Tanaka, Kenzo Yamamura

J Ocul Pharmacol Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Kathy Liu

J Glaucoma· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal refractive therapy gas permeable lenses for the correction of hyperopia after one night of lens wear.
Luigina Sorbara, Fenghe Lu

Eye Contact Lens· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malleability of the ocular surface in response to mechanical stress induced by orthokeratology contact lenses.
Fenghe Lu, Trefford Simpson, Luigina Sorbara, Desmond Fonn

Cornea· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between the treatment zone diameter and visual, optical and subjective performance in Corneal Refractive Therapy lens wearers.
Fenghe Lu, Trefford Simpson, Luigina Sorbara, Desmond Fonn

Ophthalmic Physiol Opt· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal refractive therapy with different lens materials, part 2: effect of oxygen transmissibility on corneal shape and optical characteristics.
Fenghe Lu, Trefford Simpson, Luigina Sorbara, Desmond Fonn

Optom Vis Sci· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal shape and optical performance after one night of corneal refractive therapy for hyperopia.
Fenghe Lu, Luigina Sorbara, Trefford Simpson, Desmond Fonn

Optom Vis Sci· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity of pachymetric measurements by manipulating the acoustic factor of Orbscan II.
Fenghe Lu, Trefford Simpson, Desmond Fonn, Luigina Sorbara, Lyndon Jones

Eye Contact Lens· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of myopia from corneal refractive therapy.
Luigina Sorbara, Desmond Fonn, Trefford Simpson, Fenghe Lu, Richard Kort

Optom Vis Sci· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis